Indiva Launches New CBD Products

Indiva introduces Bhang® CBD Milk Chocolate and INDIVA™ CBD Softgels


LONDON, Ontario
– June 25, 2020: Indiva Limited (the “Company” or “Indiva”) (TSXV:NDVA) (OTCQX:NDVAF) is pleased to announce the introduction of two new CBD offerings to its product portfolio. Bhang® CBD Milk Chocolate has shipped to provincial wholesalers in Ontario, Alberta, British Columbia, Manitoba, Saskatchewan, New Brunswick, and Nova Scotia. INDIVATM CBD Softgels will be available in Quebec, Ontario, Alberta, Manitoba, and Saskatchewan in early July.

“We are excited to introduce our first CBD-based products,” Niel Marotta, Indiva’s President and Chief Executive Officer, said. “Since legalization, we’ve heard from our consumers that they have a growing interest in CBD products. We saw an opportunity to leverage the popularity of our edible offerings to better serve all Canadian cannabis consumers with the first high CBD, low THC chocolate product in the market. In addition, we are excited to launch CBD softgels to complement our popular THC capsules. With these two new SKUs, we look forward to connecting with new of-age Canadians who are ready and excited to try CBD-based cannabis products.”

Bhang® CBD Milk Chocolate contains 10 mg of CBD and 0.5 mg of THC per package. Each chocolate is made with CBD distillate and sustainably-sourced cacao. It follows the same recipe as Canada’s #1 edible, Bhang® Milk Chocolate. INDIVATM CBD Softgels contain 7-9 mg of CBD per softgel. Each softgel is filled with high-quality cannabis oil and pharmaceutical-grade MCT oil. Both products are manufactured at Indiva’s state-of-the-art facility in London, Ontario.

 

About Indiva

Indiva sets the standard for quality and innovation in cannabis. As a Canadian licensed producer, Indiva creates premium pre-rolls, flower, capsules, and edible products and provides production and manufacturing services to peer entities. In Canada, Indiva produces and distributes the award-winning Bhang® Chocolate, Wana Sour Gummies, Ruby® Cannabis Sugar, Sapphire™ Cannabis Salt and other Powered by INDIVA™ products through license agreements, partnerships and joint ventures. Click here to connect with Indiva on LinkedIn, Instagram, Twitter and Facebook, and here to find more information on the Company and its products.

 

Contacts

Media Contact
Meagan Kelly, Marketing and Communications Specialist
Phone: 613-979-6347
Email: [email protected]

Investor Contact
Steve Low, Investor Relations
Phone: 647-620-5101
Email: [email protected]

 

Disclaimer and Reader Advisory

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) has in any way passed upon the merits of the contents of this press release and neither of the foregoing entities accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the parties’ current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the Company’s future operations, future product offerings and compliance with applicable regulations. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the parties. The material factors and assumptions include the parties being able to maintain the necessary regulatory and other third parties’ approvals and licensing and other risks associated with regulated entities in the cannabis industry. The forward-looking information contained in this release is made as of the date hereof and the parties are not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.

 


Subscribe to News